What is Stage IV lung cancer?
Stage IV means lung cancer has spread to distant sites — the opposite lung, pleural or pericardial effusion, or distant organs such as the brain, liver, adrenal glands, or bones. Approximately 40% of NSCLC patients are diagnosed at Stage IV, making it by far the most common presentation. While Stage IV is not curable in most cases, treatment has been transformed over the past decade: targeted therapies for driver-mutation-positive patients have pushed median survival well past two years in some populations, and immunotherapy has produced long-term responses in a meaningful subset of driver-mutation-negative patients.
Stage IV is where clinical trials offer the greatest breadth of options and the most meaningful benefit. The treatment decision tree at Stage IV is entirely guided by molecular profile first: if you have a driver mutation (EGFR, ALK, KRAS G12C, ROS1, MET exon 14, RET, NTRK), targeted therapy is the foundation and trials build from there. If no driver mutation is found, PD-L1 expression guides immunotherapy strategy. Comprehensive NGS testing before starting any first-line treatment is non-negotiable — starting chemotherapy before knowing your molecular status may close doors to trials that require treatment-naive patients.
Stage IV Substages and Special Populations
Not all Stage IV presentations are equivalent. These distinctions affect trial eligibility significantly:
Stage IV Trial Pathways: The Molecular Decision Tree
Your first-line treatment and trial eligibility at Stage IV flow entirely from molecular testing results. This is the order of decisions:
Driver Mutation Positive — First-Line
EGFR, ALK, KRAS G12C, ROS1, MET exon 14, RET, NTRK, BRAF V600E, HER2 exon 20 — if any of these are present, targeted therapy is standard first-line. Chemotherapy and immunotherapy are generally not used first-line in driver-positive patients. First-line trials in this group test the approved targeted agent against a novel combination, or compare two approved agents. See the specific biomarker pages for detailed trial guidance.
No Driver Mutation, PD-L1 ≥50% — First-Line
Pembrolizumab monotherapy is the standard. Trials are testing novel agents to improve on pembrolizumab's ~45% response rate: anti-TIGIT agents (tiragolumab, domvanalimab), anti-LAG-3 (relatlimab), anti-CTLA-4 combinations, and bispecific checkpoint inhibitors. If you're treatment-naive with high PD-L1 and no driver mutation, multiple first-line trials are likely open to you now.
No Driver Mutation, PD-L1 <50% — First-Line
Platinum-doublet chemotherapy + pembrolizumab (or atezolizumab/nivolumab) is standard. For non-squamous histology, carboplatin + pemetrexed + pembrolizumab is most common. Trials in this group test novel ADCs (antibody-drug conjugates) like datopotamab deruxtecan (Dato-DXd) as alternatives to chemotherapy, and novel immunotherapy combinations that don't rely on PD-L1 as a predictor.
After First-Line Progression — All Patients
At progression, the approach depends entirely on what you received first-line and your current molecular status (repeat biopsy often reveals new mutations). Driver-positive patients look for resistance mechanism-specific trials. Driver-negative patients who progressed on immunotherapy look for post-checkpoint inhibitor trials. This is the most heterogeneous and rapidly evolving trial space in lung oncology.
How Metastatic Sites Affect Trial Eligibility
Where your cancer has spread affects which trials you can join, often in ways that aren't obvious:
Stage IV Lung Cancer FAQs
Get comprehensive molecular testing before starting any systemic treatment. This is the single most important step. A comprehensive NGS panel testing for EGFR, ALK, KRAS G12C, ROS1, MET exon 14, RET, NTRK, BRAF V600E, HER2 exon 20, and PD-L1 IHC should be ordered on your tumor tissue immediately. If your oncologist has recommended starting chemotherapy urgently without waiting for NGS results, ask specifically whether waiting 2–3 weeks for results would be safe — in most Stage IV NSCLC cases, it is, and starting chemotherapy before knowing your molecular status can permanently close doors to first-line targeted therapy trials that require treatment-naive patients. Many of the highest-value trials in lung cancer require that you haven't received any prior systemic therapy.
Before enrolling in any second-line trial, get a repeat biopsy or liquid biopsy (ctDNA from blood) at progression. This is essential for two reasons. First, acquired resistance mutations often emerge after targeted therapy — for example, EGFR T790M after erlotinib/gefitinib, or MET amplification after osimertinib — and these new findings determine which second-line trials you qualify for. Second, tumors can evolve histologically: NSCLC can transform to SCLC after EGFR TKI therapy (in ~3–5% of cases), completely changing your treatment approach. A liquid biopsy is quick and non-invasive; a tissue biopsy provides more information. Many second-line trials now require a recent biopsy (within 3–6 months) taken after progression on prior therapy, not the original diagnostic biopsy.
Not as much as it used to. The landscape has shifted significantly over the past five years. Most modern targeted therapy trials — particularly for EGFR, ALK, and ROS1 patients — explicitly allow stable, previously treated brain metastases (typically defined as no steroids and no progression on brain MRI for at least 4 weeks before enrollment). Some trials have specific CNS cohorts designed to demonstrate intracranial efficacy. Immunotherapy trials are more variable — some exclude active untreated CNS disease; others allow it with caveats. The key steps: get a brain MRI before trial screening (most trials require one regardless), treat any symptomatic or large lesions with SRS or WBRT first if needed, then confirm stability before enrollment. Active leptomeningeal disease (cancer in the fluid around the brain and spinal cord) is a more significant barrier — many trials exclude it, though dedicated leptomeningeal trials do exist.
Oligometastatic NSCLC typically refers to patients with 1–5 metastatic lesions in ≤3 organs, all of which are amenable to local ablative treatment (stereotactic body radiation, SBRT, or surgical resection). The hypothesis is that aggressively treating all sites of disease — rather than just using systemic therapy — might produce longer remissions or occasionally long-term control. Several randomized trials have shown improved progression-free survival with local ablative therapy added to systemic treatment in oligometastatic NSCLC (SINDAS, STEREOSABR). Active trials are defining the optimal patient selection criteria, the best systemic therapy backbone, and whether local consolidation benefits driver-mutation-positive and driver-mutation-negative patients equally. If you have Stage IVA with limited metastatic sites, specifically ask your oncologist whether you meet criteria for an oligometastatic trial — this is often not raised proactively.
(1) Comprehensive NGS report — the actual report with all molecular results, not a summary. Many trials verify specific mutations, variant allele frequencies, and testing methodology. (2) PD-L1 IHC result with TPS percentage and clone used (22C3 for pembrolizumab trials, SP142 for atezolizumab trials). (3) Recent CT scan chest/abdomen/pelvis showing measurable disease per RECIST 1.1 — trials need at least one target lesion ≥10mm. Most trials require imaging within 4–6 weeks of enrollment. (4) Brain MRI — required by nearly all modern Stage IV trials, within 4–8 weeks of enrollment, even in asymptomatic patients. (5) Complete prior treatment history including every regimen, dates, best response, and reason for stopping — second-line and beyond trials almost always have specific prior therapy requirements. (6) ECOG performance status 0–1 documented by your oncologist. (7) Recent labs — CBC, comprehensive metabolic panel, LFTs within 2 weeks of enrollment.
Ready to find your matching Stage IV trials?
Upload your NGS report, pathology results, or imaging. We'll map your molecular profile and treatment history to recruiting trials and give you a full eligibility breakdown.